Early Intervention Efficacy of Tiotropium/Olodaterol Compared to Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (Early Intervention Efficacy in COPD)

Study identification

• EU PAS number:
  EUPAS33426
• Study ID:
  33674
• Official title and acronym:
  Early Intervention Efficacy of Tiotropium/Olodaterol Compared to Tiotropium in Chronic Obstructive Pulmonary Disease (COPD) (Early Intervention Efficacy in COPD)
• DARWIN EU® study:
  No
• Study countries:
  Japan
• Study description:
  This study aims to evaluate the time to escalation to triple therapy among the Japanese Chronic obstructive pulmonary disease (COPD) patients newly initiating therapy with a combination of Olodaterol and Tiotropium (herein referred to as Tio/Olo) using real world data.
• Study status:
  Ongoing

Research institutions and networks

Institutions

Boehringer Ingelheim

Study timelines

Date when funding contract was signed

Actual: 19/07/2019

Study start date

Actual: 28/09/2015

Date of final study report

Planned: 30/05/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable

Other study registration identification numbers and links

ClinicalTrials.gov Identifier: NCT04249310 (https://www.clinicaltrials.gov/ct2/show/NCT04249310?term=Spiolto&draw=3&rank=19)Other Study ID Numbers: 1237-0100